Financhill
Sell
49

VTRS Quote, Financials, Valuation and Earnings

Last price:
$12.4000
Seasonality move :
12.93%
Day range:
$12.1200 - $12.4100
52-week range:
$9.9250 - $13.6175
Dividend yield:
3.87%
P/E ratio:
--
P/S ratio:
0.99x
P/B ratio:
0.75x
Volume:
4M
Avg. volume:
9.1M
1-year change:
16.43%
Market cap:
$14.8B
Revenue:
$15.4B
EPS (TTM):
-$0.74

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VTRS
Viatris
$3.7B $0.68 -5.73% 150.87% --
BAX
Baxter International
$3.8B $0.78 -62.77% 8.2% --
CATX
Perspective Therapeutics
$237.9K -$0.20 -- -70.12% $16.15
GILD
Gilead Sciences
$7B $1.55 0.56% 49.61% $98.92
LXRX
Lexicon Pharmaceuticals
$2.9M -$0.17 910.29% -37.45% $3.60
MRNA
Moderna
$1.2B -$1.94 -63.53% -79.68% $127.09
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VTRS
Viatris
$12.4000 -- $14.8B -- $0.12 3.87% 0.99x
BAX
Baxter International
$29.08 -- $14.8B 145.40x $0.17 3.58% 0.86x
CATX
Perspective Therapeutics
$3.25 $16.15 $219.7M -- $0.00 0% 17.55x
GILD
Gilead Sciences
$93.95 $98.92 $117.1B 1,043.89x $0.77 3.28% 4.16x
LXRX
Lexicon Pharmaceuticals
$0.76 $3.60 $273.9M -- $0.00 0% 42.13x
MRNA
Moderna
$40.27 $127.09 $15.5B -- $0.00 0% 3.08x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VTRS
Viatris
44.31% 0.857 113.66% 0.80x
BAX
Baxter International
62.17% 0.313 66.5% 0.51x
CATX
Perspective Therapeutics
-- -5.312 -- --
GILD
Gilead Sciences
55.72% 0.574 22.27% 0.82x
LXRX
Lexicon Pharmaceuticals
35.88% 1.185 17.6% 7.25x
MRNA
Moderna
-- 0.826 -- 3.95x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VTRS
Viatris
$1.5B $257.4M -2.35% -4.39% 6.29% $741.1M
BAX
Baxter International
$1B $150M 0.49% 1.33% 6.3% $229M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
GILD
Gilead Sciences
$6B $3.1B 0.29% 0.64% 15.83% $4.2B
LXRX
Lexicon Pharmaceuticals
$1.7M -$63.7M -75.24% -115.11% -3442.8% -$53.9M
MRNA
Moderna
$1.3B -$70M -17.44% -17.44% 1.46% -$1.7B

Viatris vs. Competitors

  • Which has Higher Returns VTRS or BAX?

    Baxter International has a net margin of 2.53% compared to Viatris's net margin of 5.19%. Viatris's return on equity of -4.39% beat Baxter International's return on equity of 1.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTRS
    Viatris
    38.9% $0.08 $35.5B
    BAX
    Baxter International
    38.27% $0.27 $20.9B
  • What do Analysts Say About VTRS or BAX?

    Viatris has a consensus price target of --, signalling upside risk potential of 8.47%. On the other hand Baxter International has an analysts' consensus of -- which suggests that it could grow by 39.93%. Given that Baxter International has higher upside potential than Viatris, analysts believe Baxter International is more attractive than Viatris.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTRS
    Viatris
    1 6 0
    BAX
    Baxter International
    0 0 0
  • Is VTRS or BAX More Risky?

    Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Baxter International has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.462%.

  • Which is a Better Dividend Stock VTRS or BAX?

    Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.87%. Baxter International offers a yield of 3.58% to investors and pays a quarterly dividend of $0.17 per share. Viatris pays 1052.29% of its earnings as a dividend. Baxter International pays out 22.06% of its earnings as a dividend. Baxter International's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Viatris's is not.

  • Which has Better Financial Ratios VTRS or BAX?

    Viatris quarterly revenues are $3.8B, which are larger than Baxter International quarterly revenues of $2.7B. Viatris's net income of $94.8M is lower than Baxter International's net income of $140M. Notably, Viatris's price-to-earnings ratio is -- while Baxter International's PE ratio is 145.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.99x versus 0.86x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTRS
    Viatris
    0.99x -- $3.8B $94.8M
    BAX
    Baxter International
    0.86x 145.40x $2.7B $140M
  • Which has Higher Returns VTRS or CATX?

    Perspective Therapeutics has a net margin of 2.53% compared to Viatris's net margin of --. Viatris's return on equity of -4.39% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VTRS
    Viatris
    38.9% $0.08 $35.5B
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About VTRS or CATX?

    Viatris has a consensus price target of --, signalling upside risk potential of 8.47%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than Viatris, analysts believe Perspective Therapeutics is more attractive than Viatris.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTRS
    Viatris
    1 6 0
    CATX
    Perspective Therapeutics
    8 1 0
  • Is VTRS or CATX More Risky?

    Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

  • Which is a Better Dividend Stock VTRS or CATX?

    Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.87%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays 1052.29% of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTRS or CATX?

    Viatris quarterly revenues are $3.8B, which are larger than Perspective Therapeutics quarterly revenues of --. Viatris's net income of $94.8M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Viatris's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.99x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTRS
    Viatris
    0.99x -- $3.8B $94.8M
    CATX
    Perspective Therapeutics
    17.55x -- -- -$15.1M
  • Which has Higher Returns VTRS or GILD?

    Gilead Sciences has a net margin of 2.53% compared to Viatris's net margin of 16.61%. Viatris's return on equity of -4.39% beat Gilead Sciences's return on equity of 0.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTRS
    Viatris
    38.9% $0.08 $35.5B
    GILD
    Gilead Sciences
    79.14% $1.00 $41.6B
  • What do Analysts Say About VTRS or GILD?

    Viatris has a consensus price target of --, signalling upside risk potential of 8.47%. On the other hand Gilead Sciences has an analysts' consensus of $98.92 which suggests that it could grow by 5.29%. Given that Viatris has higher upside potential than Gilead Sciences, analysts believe Viatris is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTRS
    Viatris
    1 6 0
    GILD
    Gilead Sciences
    13 12 0
  • Is VTRS or GILD More Risky?

    Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.175, suggesting its less volatile than the S&P 500 by 82.499%.

  • Which is a Better Dividend Stock VTRS or GILD?

    Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.87%. Gilead Sciences offers a yield of 3.28% to investors and pays a quarterly dividend of $0.77 per share. Viatris pays 1052.29% of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Viatris's is not.

  • Which has Better Financial Ratios VTRS or GILD?

    Viatris quarterly revenues are $3.8B, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Viatris's net income of $94.8M is lower than Gilead Sciences's net income of $1.3B. Notably, Viatris's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 1,043.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.99x versus 4.16x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTRS
    Viatris
    0.99x -- $3.8B $94.8M
    GILD
    Gilead Sciences
    4.16x 1,043.89x $7.5B $1.3B
  • Which has Higher Returns VTRS or LXRX?

    Lexicon Pharmaceuticals has a net margin of 2.53% compared to Viatris's net margin of -3703.49%. Viatris's return on equity of -4.39% beat Lexicon Pharmaceuticals's return on equity of -115.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTRS
    Viatris
    38.9% $0.08 $35.5B
    LXRX
    Lexicon Pharmaceuticals
    95.94% -$0.18 $278.4M
  • What do Analysts Say About VTRS or LXRX?

    Viatris has a consensus price target of --, signalling upside risk potential of 8.47%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $3.60 which suggests that it could grow by 375.06%. Given that Lexicon Pharmaceuticals has higher upside potential than Viatris, analysts believe Lexicon Pharmaceuticals is more attractive than Viatris.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTRS
    Viatris
    1 6 0
    LXRX
    Lexicon Pharmaceuticals
    2 2 0
  • Is VTRS or LXRX More Risky?

    Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.862%.

  • Which is a Better Dividend Stock VTRS or LXRX?

    Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.87%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays 1052.29% of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTRS or LXRX?

    Viatris quarterly revenues are $3.8B, which are larger than Lexicon Pharmaceuticals quarterly revenues of $1.8M. Viatris's net income of $94.8M is higher than Lexicon Pharmaceuticals's net income of -$64.8M. Notably, Viatris's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.99x versus 42.13x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTRS
    Viatris
    0.99x -- $3.8B $94.8M
    LXRX
    Lexicon Pharmaceuticals
    42.13x -- $1.8M -$64.8M
  • Which has Higher Returns VTRS or MRNA?

    Moderna has a net margin of 2.53% compared to Viatris's net margin of 0.7%. Viatris's return on equity of -4.39% beat Moderna's return on equity of -17.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTRS
    Viatris
    38.9% $0.08 $35.5B
    MRNA
    Moderna
    72.29% $0.03 $11.9B
  • What do Analysts Say About VTRS or MRNA?

    Viatris has a consensus price target of --, signalling upside risk potential of 8.47%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 84.23%. Given that Moderna has higher upside potential than Viatris, analysts believe Moderna is more attractive than Viatris.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTRS
    Viatris
    1 6 0
    MRNA
    Moderna
    7 12 1
  • Is VTRS or MRNA More Risky?

    Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

  • Which is a Better Dividend Stock VTRS or MRNA?

    Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.87%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays 1052.29% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTRS or MRNA?

    Viatris quarterly revenues are $3.8B, which are larger than Moderna quarterly revenues of $1.9B. Viatris's net income of $94.8M is higher than Moderna's net income of $13M. Notably, Viatris's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.99x versus 3.08x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTRS
    Viatris
    0.99x -- $3.8B $94.8M
    MRNA
    Moderna
    3.08x -- $1.9B $13M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
87
PSIX alert for Dec 25

Power Solutions International [PSIX] is up 27.42% over the past day.

Buy
65
TSLL alert for Dec 25

Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.

Buy
75
SMLR alert for Dec 25

Semler Scientific [SMLR] is up 15.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock